Neuropharmacological profiles of a novel atypical antipsychotic, NRA0562, in rats

European Journal of Pharmacology

Volumn 423, Issue 1, 2001, Pages 27-33

  Kawashima, Naoya ^a   Funakoshi, Takeo ^a   Omura, Tomohiro ^a   Chaki, Shigeyuki ^a   Kameo, Kazuya ^a   Okuyama, Shigeru ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Dopamine neuron; Electrophysiology; Fos like immunoreactivity; NRA0562; Risperidone

Indexed keywords

5 [2 [4 (6 FLUORO 1H INDOLE 3 YL)PIPERIDINE 1 YL]ETHYL] 4 (4 FLUOROPHENYL)THIAZOLE 2 CARBOXYLIC ACID AMIDE; METHAMPHETAMINE; NEUROLEPTIC AGENT; NRA 0562; PROTEIN FOS; RISPERIDONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; ELECTROPHYSIOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NERVE CONDUCTION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT;

ACTION POTENTIALS; ANIMALS; ANTIPSYCHOTIC AGENTS; CORPUS STRIATUM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOHISTOCHEMISTRY; MALE; METHAMPHETAMINE; NEURONS; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, WISTAR; RISPERIDONE; THIAZOLES;

EID: 0035967935     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)01085-8     Document Type: Article

References (32)

1. Prazocin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not in the nigrostriatal dopaminergic system
2. Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prozosin, an alpha-1 noradrenergic antagonist
3. Dopamine and the pathophysiology of dyskinesias induced by antipsychotic compounds
4. Central dopaminergic systems: Two in vivo electrophysiological models for predicting therapeutic efficacy and neurological side effects of putative antipsychotic drugs
5. Electrophysiological effects of amphetamine on dopaminergic neurons
6. The effect of antipsychotic drugs on the firing of dopaminergic neurons: A reappraisal
7. Representation of the body by single neurons in the dorsolateral striatum of the awake, unrestrained rat
8. 2 and 5-HT2 antagonist risperidone (R64766) in the treatment of chronic psychosis. An open dose-finding study
9. Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons
10. A Canadian multicentre placebo-controlled study in fixed doses of risperidone and halopridol in the treatment of schizophrenic patients
11. The risks and benefits of clozapine versus clorpromazine
12. The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: Cellular localization and pharmacological characterization
13. Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: The nucleus accumbens shell as a locus of antipsychotic action
14. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs
15. Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain
16. Seroquel: Electrophysiological profile of a potential atypical antipsychotic
17. Receptor mechanisms mediating clozapine-induced c-fos expression in the forebrain
18. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
19. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin 2 pKi values
20. Differential induction of neurotensin and c-fos gene expression by typical and atypical antipsychotics
21. Clozapine's effect on negative symptoms in treatment-refractory schizophrenics
22. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine 2A receptor antagonist, in rats
23. Motor functions of the striatum of the rat: Critical role of the lateral region in tongue and forelimb reaching
24. Neuroleptics increase c-fos expression in the forebrain: Contrasting effects of haloperidol and clozapine
25. Induction patterns of neuroleptic-induced Fos-like immunoreactivity as predictors of atypical antipsychotic activity
26. Risperidone (R64766) in psychotic patients: A first clinical therapeutic exploration
27. Dopamine receptors, neuroleptics and schizophrenia
28. Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells
29. Mode of action of atypical neuroleptics in relation to the pehncyclidine model of schizophrenia: Role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism
30. Clozapine: A review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents
31. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons